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Background
Hu and colleagues have identified tissue factor (TF-the
primary initiator of coagulation and a modulator of angio-
genesis) as a common yet specific biomarker and thera-
peutic target on a variety of cancer cells and angiogenic
tumor vascular endothelial cells [1-3]. He has co-invented
a TF-targeting Immuno-Conjugate agent named ICON
that consists of factor VII (1-406 aa, the natural ligand to
tissue factor) fused to the Fc region of IgG1 [1, 2, 4, 5].
Intra-lesional ICON therapy of experimental murine mela-
noma tumors with an adenoviral vector leads to marked
growth tumor inhibition with minimal effects on normal
tissues [1]. However, ICON has a relatively big molecular
weight (210 kDa) (Figure 1) [5]. To reduce its molecular
mass, Hu has developed a second generation ICON, named
L-ICON, which consists of only the light chain (1-152 aa)
of fVII fused to IgG1Fc (Figure 1). This proposal is
designed to evaluate the effects of L-ICON immunotherapy
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for the treatment of BRAF mutated melanoma and triple
negative breast cancer (TNBC), both of which are very diffi-
cult to treat in clinic.
Methods
L-ICON protein and adenoviral vectors have been devel-
oped by recombinant DNA techniques. The binding activ-
ity of L-ICON to human melanoma lines with or without
BRAF mutant and to human TNBC was assayed by flow
cytometry and cell ELISA. Its ADCC effect was deter-
mined by an ADCC effector assay (Promega). L-ICON
therapy of TNBC via intra-lesional injection of Ad-L-
ICON was compared to Ad-ICON in a nude mouse
model of TNBC MDA-MB-231.
Results
The molecular weight of L-ICON was 100 kDa (Fig. 1),
only 50% of ICON’s. L-ICON could bind to human and
canine melanoma lines, regardless of their BRAF status.
L-ICON could also bind to human TNBC lines, similarly
to the first generation ICON. L-ICON could mediate
ADCC effect to these cancer cells in vitro. Intra-lesional
L-ICON and ICON immunotherapy via adenoviral vec-
tors were similarly effective for the treatment of human
TNBC in a nude mouse model.
Conclusions
L-ICON molecular mass was reduced significantly while
its binding activity to cancer cells was intact. L-ICON
therapy was effective for the treatment of melanoma and
TNBC in vitro and in vivo in a preclinical mouse model.
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